# Adagio Therapeutics Inc. (ADGI)

Source: https://www.quantisnow.com/company/ADGI
Generated: 2026-11-11T07:07:05.668Z

- Ticker: ADGI
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: adagiotx.com

## About

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.

## Latest ADGI news and filings

- 2023-02-28 12:00 UTC [Conference Announcement] [Invivyd to Participate at Cowen's 43rd Annual Healthcare Conference](https://www.quantisnow.com/insight/invivyd-to-participate-at-cowens-43rd-annual-healthcare-conference-4128361)
- 2023-02-03 12:30 UTC [Invivyd Announces Changes to Executive Team](https://www.quantisnow.com/insight/invivyd-announces-changes-to-executive-team-3999422)
- 2023-01-09 12:11 UTC [SEC Form 8-K] [Adagio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adagio-therapeutics-inc-filed-sec-form-8-k-other-events-financial-3886866)
- 2022-12-19 12:00 UTC [Conference Announcement] [Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop](https://www.quantisnow.com/insight/invivyd-presented-joint-industry-rationale-on-potential-expedited-development-pathways-3820237)
- 2022-12-16 22:20 UTC [SEC Form 4] [SEC Form 4 filed by Dabora Rebecca](https://www.quantisnow.com/insight/sec-form-4-filed-by-dabora-rebecca-3818721)
- 2022-12-16 22:16 UTC [SEC Form 4] [SEC Form 4 filed by Andersen Jill](https://www.quantisnow.com/insight/sec-form-4-filed-by-andersen-jill-3818692)
- 2022-12-16 22:14 UTC [SEC Form 4] [SEC Form 4 filed by Schmidt Peter](https://www.quantisnow.com/insight/sec-form-4-filed-by-schmidt-peter-3818666)
- 2022-12-16 22:11 UTC [SEC Form 4] [SEC Form 4 filed by Gowler Jeremy](https://www.quantisnow.com/insight/sec-form-4-filed-by-gowler-jeremy-3818644)
- 2022-12-16 22:10 UTC [SEC Form 3] [SEC Form 3 filed by new insider Gowler Jeremy](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-gowler-jeremy-3818624)
- 2022-12-16 22:09 UTC [SEC Form 4] [SEC Form 4 filed by Hering David](https://www.quantisnow.com/insight/sec-form-4-filed-by-hering-david-3818622)
- 2022-12-06 22:55 UTC [SEC Form 4] [SEC Form 4 filed by Schmidt Peter](https://www.quantisnow.com/insight/sec-form-4-filed-by-schmidt-peter-3775303)
- 2022-12-06 22:52 UTC [SEC Form 3] [SEC Form 3: New insider Schmidt Peter claimed ownership of 6,971 shares](https://www.quantisnow.com/insight/sec-form-3-new-insider-schmidt-peter-claimed-ownership-of-3775286)
- 2022-12-06 21:28 UTC [SEC Form 8-K] [Adagio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adagio-therapeutics-inc-filed-sec-form-8-k-leadership-update-other-3774677)
- 2022-12-06 21:01 UTC [Leadership Update] [Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer](https://www.quantisnow.com/insight/invivyd-appoints-jeremy-gowler-as-chief-operating-and-commercial-officer-3774238)
- 2022-11-29 22:16 UTC [SEC Form D] [SEC Form D filed by Adagio Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-adagio-therapeutics-inc-3746544)
- 2022-11-17 12:10 UTC [SEC Form 8-K] [Adagio Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adagio-therapeutics-inc-filed-sec-form-8-k-entry-into-a-3700472)
- 2022-11-17 12:00 UTC [Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19](https://www.quantisnow.com/insight/invivyd-announces-partnership-with-population-health-partners-to-accelerate-clinical-3700281)
- 2022-11-10 21:26 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Adagio Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-adagio-therapeutics-inc-3668211)
- 2022-11-10 21:13 UTC [SEC Form 8-K] [Adagio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adagio-therapeutics-inc-filed-sec-form-8-k-results-of-operations-3667769)
- 2022-11-10 21:01 UTC [Earnings Date] [Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights](https://www.quantisnow.com/insight/invivyd-reports-third-quarter-2022-financial-results-and-business-highlights-3667016)
- 2022-11-09 12:00 UTC [Conference Announcement] [Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference](https://www.quantisnow.com/insight/invivyd-to-participate-in-fireside-chat-at-the-jefferies-london-3653861)
- 2022-11-04 20:06 UTC [SEC Form 4] [SEC Form 4 filed by Andersen Jill](https://www.quantisnow.com/insight/sec-form-4-filed-by-andersen-jill-3635897)
- 2022-11-02 11:00 UTC [Earnings Date] [Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/invivyd-to-host-conference-call-on-november-10-to-discuss-3614453)
- 2022-10-24 20:52 UTC [SEC Form 4] [SEC Form 4 filed by Lindenboom Christine](https://www.quantisnow.com/insight/sec-form-4-filed-by-lindenboom-christine-3569049)
- 2022-10-24 20:50 UTC [SEC Form 3] [SEC Form 3 filed by new insider Lindenboom Christine](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-lindenboom-christine-3569042)
- 2022-10-24 20:30 UTC [SEC Form 8-K] [Adagio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adagio-therapeutics-inc-filed-sec-form-8-k-leadership-update-regulation-3568888)
- 2022-10-24 20:01 UTC [Leadership Update] [Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors](https://www.quantisnow.com/insight/invivyd-announces-the-appointment-of-christine-lindenboom-to-board-of-3568443)
- 2022-10-13 20:53 UTC [SEC Form 3] [SEC Form 3 filed by new insider Driscoll Frederick W](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-driscoll-frederick-w-3530781)
- 2022-10-13 20:16 UTC [SEC Form 8-K] [Adagio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adagio-therapeutics-inc-filed-sec-form-8-k-leadership-update-regulation-3530461)
- 2022-10-13 20:01 UTC [Leadership Update] [Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform](https://www.quantisnow.com/insight/invivyd-appoints-fred-driscoll-as-interim-chief-financial-officer-and-3530207)
- 2022-10-12 20:01 UTC [Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022](https://www.quantisnow.com/insight/invivyd-to-present-multiple-posters-highlighting-clinical-data-from-adintrevimab-3524685)
- 2022-10-06 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Adagio Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-adagio-therapeutics-inc-3500728)
- 2022-09-28 21:08 UTC [SEC Form S-3] [SEC Form S-3 filed by Adagio Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-adagio-therapeutics-inc-3468001)
- 2022-09-13 11:30 UTC [SEC Form 8-K] [Adagio Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adagio-therapeutics-inc-filed-sec-form-8-k-amendments-to-articles-3403362)
- 2022-09-12 11:46 UTC [SEC Form 8-K] [Adagio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/adagio-therapeutics-inc-filed-sec-form-8-k-other-events-financial-3397831)
- 2022-09-12 11:18 UTC [Market Insight] [Invivyd Announces COVID-19 Antibody Candidates](https://www.quantisnow.com/insight/invivyd-announces-covid-19-antibody-candidates-3397657)
- 2022-09-12 11:15 UTC [Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants](https://www.quantisnow.com/insight/invivyd-announces-multiple-next-generation-covid-19-antibody-candidates-and-selects-3397645)
- 2022-09-12 11:07 UTC [Market Chatter] [Adagio Therapeutics Announces Corporate Name Change To Invivyd; The Company Will Begin Trading Under The New Ticker Symbol "IVVD" On The Nasdaq Global Market At Market Open On September 13, 2022](https://www.quantisnow.com/insight/adagio-therapeutics-announces-corporate-name-change-to-invivyd-the-company-3397600)
- 2022-09-12 11:00 UTC [Adagio Therapeutics Announces Corporate Name Change to Invivyd](https://www.quantisnow.com/insight/adagio-therapeutics-announces-corporate-name-change-to-invivyd-3397529)
- 2022-09-06 20:01 UTC [Conference Announcement] [Adagio Therapeutics to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/adagio-therapeutics-to-participate-in-upcoming-investor-conferences-3377989)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ADGI
- Earnings history: https://www.quantisnow.com/earnings/ADGI
- Dividend history: https://www.quantisnow.com/dividends/ADGI
- Insider transactions: https://www.quantisnow.com/insiders/ADGI
- Options chain: https://www.quantisnow.com/options/ADGI
- SEC 8-K filings only: https://www.quantisnow.com/company/ADGI/8-k
- RSS and alerts for ADGI: https://www.quantisnow.com/docs/rss-feeds.md